The US Food and Drug Administration (FDA) has granted clearance of the EYE-SYNC technology as an Aid to Concussion, or mild Traumatic Brain Injury (mTBI) Diagnosis, SyncThink — a next gen neurotechnology company and developer of the award-winning EYE-SYNC technology — announces.

EYE-SYNC previously received Breakthrough Device Designation from the FDA in 2019, following the initial clearance and commercialization of the technology platform in 2017, according to a media release from the Palo Alto, Calif-based company.

“After a decade of clinical research, 30 publications, and 16 patents, we are pleased to formally extend EYE-SYNC’s indications to the many providers who will benefit from rapid, objective diagnostic technology. Concussion is a complex condition and a challenge for many clinicians to manage, so we hope that by offering highly accurate diagnostic tools and proven algorithms, we will help providers and their patients identify the most effective and appropriate treatment.”

— SyncThink founder and Stanford University Professor Jam Ghajar, MD, PhD

In support of the application, SyncThink enrolled 1,655 pediatric and adult subjects into a clinical study that collected comprehensive patient and concussion-related data for over 1 year. Utilizing this information, SyncThink implemented proprietary algorithms and deep learning models to identify a positive or negative indication of concussion. The study showed that EYE-SYNC demonstrated sensitivity above 82% and specificity above 93%, thereby providing clinicians with significant and actionable data when evaluating individuals with concussion.

“The outcome of this study very clearly shows the effectiveness of our technology at detecting concussion, and definitively demonstrates the clinical utility of EYE-SYNC. It also shows that the future of concussion diagnosis is no longer purely symptom based, but that of a technology driven multi-modal approach.”

— SyncThink Chief Clinical Officer Scott Anderson

The EYE-SYNC technology utilizes a series of 60-second eye tracking assessments, neurocognitive batteries, symptom inventories, and standardized patient inventories to identify the type and severity of dysfunction after concussion. The platform generates customizable and interpretive reports that support clinical decision-making, and offers visual and vestibular therapies to remedy deficits and monitor improvement over time.

To learn more about EYE-SYNC, visit SyncThink.

[Source: SyncThink]

Related Content:
Brain Health Organizations SyncThink and TeachAids Announce Partnership
SyncThink Eye-Tracking Technology Receives Its 14th Patent
EYE-SYNC Platform Receives FDA Breakthrough Device Nod